Inhibrx Biosciences, Inc.
General ticker "INBX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $344.3M (TTM average)
Inhibrx Biosciences, Inc. follows the US Stock Market performance with the rate: 44.4%.
Estimated limits based on current volatility of 3.3%: low 70.90$, high 75.67$
Factors to consider:
- Total employees count: 1000000 (+581295.3%) as of 2024
- Top business risk factors: Economic downturns and volatility, Intellectual property risks, Product liability, Labor/talent shortage/retention, Cybersecurity threats
- Current price 329.8% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [7.41$, 17.30$]
- 2025-12-31 to 2026-12-31 estimated range: [7.44$, 16.82$]
Financial Metrics affecting the INBX estimates:
- Positive: with PPE of 0.1 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -91.55 <= 0.04
- Negative: negative Industry operating cash flow (median)
- Positive: Shareholder equity ratio, % of 73.90 > 64.17
Short-term INBX quotes
Long-term INBX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $2.19MM | $1.80MM | $0.20MM |
| Operating Expenses | $131.31MM | $221.02MM | $331.65MM |
| Operating Income | $-129.12MM | $-219.22MM | $-331.45MM |
| Non-Operating Income | $-16.11MM | $-20.50MM | $2,019.02MM |
| Interest Expense | $18.18MM | $31.84MM | $13.49MM |
| R&D Expense | $110.19MM | $191.64MM | $203.74MM |
| Income(Loss) | $-145.22MM | $-239.72MM | $1,687.57MM |
| Taxes | $0.00MM | $0.00MM | $0.00MM |
| Other Income(Loss) | $0.00MM | $-1.63MM | $0.00MM |
| Profit(Loss)* | $-145.23MM | $-243.00MM | $1,687.57MM |
| Stockholders Equity | $58.06MM | $43.50MM | $133.58MM |
| Assets | $290.88MM | $307.89MM | $180.77MM |
| Operating Cash Flow | $-115.30MM | $-193.31MM | $-194.41MM |
| Capital expenditure | $0.69MM | $4.59MM | $2.60MM |
| Investing Cash Flow | $-0.69MM | $-4.59MM | $-2.60MM |
| Financing Cash Flow | $258.55MM | $201.96MM | $71.68MM |
| Earnings Per Share** | $-3.62 | $-5.16 | $116.58 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.